DK0626387T3 - Nukleosider og oligonukleotider med 2'-ethergrupper - Google Patents

Nukleosider og oligonukleotider med 2'-ethergrupper

Info

Publication number: DK0626387T3
Authority: DK; Denmark
Prior art keywords: alkyl; hydrogen; formula; radical; nucleosides
Prior art date: 1993-05-12

Application number

DK94810255T

Other languages

English (en)

Inventor

Pierre Dr Martin

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-12

Filing date

1994-05-03

Publication date

1999-09-27

1994-05-03 Application filed by Novartis Ag filed Critical Novartis Ag

1999-09-27 Application granted granted Critical

1999-09-27 Publication of DK0626387T3 publication Critical patent/DK0626387T3/da

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
239000002777 nucleoside Substances 0.000 title 1
125000003835 nucleoside group Chemical group 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 5
239000001257 hydrogen Substances 0.000 abstract 5
125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 3
150000002431 hydrogen Chemical group 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
229910052698 phosphorus Inorganic materials 0.000 abstract 1
239000011574 phosphorus Substances 0.000 abstract 1
125000006239 protecting group Chemical group 0.000 abstract 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
125000000714 pyrimidinyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)

DK94810255T 1993-05-12 1994-05-03 Nukleosider og oligonukleotider med 2'-ethergrupper DK0626387T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH146793		1993-05-12

Publications (1)

Publication Number	Publication Date
DK0626387T3 true DK0626387T3 (da)	1999-09-27

Family

ID=4211171

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94810255T DK0626387T3 (da)	1993-05-12	1994-05-03	Nukleosider og oligonukleotider med 2'-ethergrupper

Country Status (11)

Country	Link
US (1)	US5969116A (da)
EP (1)	EP0626387B1 (da)
JP (1)	JP4012579B2 (da)
CN (1)	CN1100728A (da)
AT (1)	ATE177430T1 (da)
AU (1)	AU687796B2 (da)
CA (1)	CA2123241C (da)
DE (1)	DE59407895D1 (da)
DK (1)	DK0626387T3 (da)
ES (1)	ES2128535T3 (da)
IL (3)	IL109605A (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5789573A (en) *	1990-08-14	1998-08-04	Isis Pharmaceuticals, Inc.	Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
ATE244723T1 (de) *	1994-04-27	2003-07-15	Novartis Pharma Gmbh	Nukleoside und oligonukleotide mit 2'- ethergruppen
DE69636160D1 (de)	1995-03-06	2006-06-29	Isis Pharmaceuticals Inc	Verfahren zur synthese von 2'-0-substituierten pyrimidinen und oligomere davon
US6166197A (en) *	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US20110028350A1 (en) *	1995-12-15	2011-02-03	Affymetrix, Inc.	Photocleavable protecting groups
US6147205A (en) *	1995-12-15	2000-11-14	Affymetrix, Inc.	Photocleavable protecting groups and methods for their use
EP0882061B1 (en)	1996-02-14	2004-05-19	Isis Pharmaceuticals, Inc.	Sugar-modified gapped oligonucleotides
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
WO1997046569A2 (en) *	1996-06-06	1997-12-11	Novartis Ag	2'-substituted nucleosides and oligonucleotide derivatives
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
EP0979309A4 (en) *	1997-04-30	2000-10-18	Isis Pharmaceuticals Inc	OLIGONUCLEOTIDES WITH IMPROVED BIOAVAILABILITY
US20040063618A1 (en) *	2002-09-30	2004-04-01	Muthiah Manoharan	Peptide nucleic acids having improved uptake and tissue distribution
US20040186071A1 (en)	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
US6093807A (en) *	1999-03-19	2000-07-25	Isis Pharmaceuticals, Inc.	Sugar-modified 7-deaza-7-substituted oligonucleotides
JP2005523232A (ja) *	2000-09-11	2005-08-04	アフィメトリックスインコーポレイテッド	光切断可能保護基
US20030027169A1 (en) *	2000-10-27	2003-02-06	Sheng Zhang	One-well assay for high throughput detection of single nucleotide polymorphisms
DE10238723A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de)	2002-08-23	2004-03-04	Bayer Ag	Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
WO2004044133A2 (en)	2002-11-05	2004-05-27	Isis Pharmaceuticals, Inc.	Modified oligonucleotides for use in rna interference
DE10320785A1 (de)	2003-05-09	2004-11-25	Bayer Healthcare Ag	6-Arylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en)	2003-05-09	2011-10-25	Boehringer Ingelheim International Gmbh	6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE102004001873A1 (de)	2004-01-14	2005-09-29	Bayer Healthcare Ag	Cyanopyrimidinone
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
US7297686B2 (en) *	2004-11-16	2007-11-20	Hwang David L	Chromium complex with insulin-like activity
US7547775B2 (en)	2004-12-31	2009-06-16	Affymetrix, Inc.	Parallel preparation of high fidelity probes in an array format
US8338093B2 (en) *	2004-12-31	2012-12-25	Affymetrix, Inc.	Primer array synthesis and validation
MX2007007184A (es)	2005-05-05	2008-01-14	Antisense Pharma Gmbh	Uso de bajas dosis de oligonucleotidos antisentido para tgf-beta, vegf, interleucina-10, c-jun, c-fos o genes e2 de prostaglandina en el tratamiento de tumores.
NZ574390A (en)	2006-06-28	2012-04-27	Coh Inc	Fatty acid blends and uses therefor in fuel
US7820810B2 (en)	2007-03-19	2010-10-26	Isis Pharmaceuticals, Inc.	Process for the synthesis of 2′-O-substituted purine nulceosides
ES2641290T3 (es)	2007-11-20	2017-11-08	Ionis Pharmaceuticals, Inc	Modulación de la expresión de CD40
CA2706018C (en)	2007-11-30	2015-11-24	Boehringer Ingelheim International Gmbh	1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
AU2009213147A1 (en)	2008-02-11	2009-08-20	Rxi Pharmaceuticals Corp.	Modified RNAi polynucleotides and uses thereof
UA105362C2 (en)	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US8815818B2 (en)	2008-07-18	2014-08-26	Rxi Pharmaceuticals Corporation	Phagocytic cell delivery of RNAI
BRPI0918527A2 (pt)	2008-09-08	2015-12-01	Boehring Ingelheim Internat Gmbh	compostos para o tratamento de disturbios do cns
EP2340309A2 (en)	2008-09-22	2011-07-06	Rxi Pharmaceuticals Corporation	Neutral nanotransporters
WO2010048585A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
EP2358397B1 (en)	2008-10-24	2020-01-01	Ionis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
WO2010059226A2 (en)	2008-11-19	2010-05-27	Rxi Pharmaceuticals Corporation	Inhibition of map4k4 through rnai
WO2010078536A1 (en)	2009-01-05	2010-07-08	Rxi Pharmaceuticals Corporation	Inhibition of pcsk9 through rnai
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2010101951A1 (en) *	2009-03-02	2010-09-10	Alnylam Pharmaceuticals, Inc.	Nucleic acid chemical modifications
NZ594567A (en)	2009-03-31	2013-12-20	Boehringer Ingelheim Int	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
TW201118099A (en) *	2009-08-12	2011-06-01	Boehringer Ingelheim Int	New compounds for the treatment of CNS disorders
CN103200945B (zh)	2010-03-24	2016-07-06	雷克西制药公司	眼部症候中的rna干扰
US9080171B2 (en)	2010-03-24	2015-07-14	RXi Parmaceuticals Corporation	Reduced size self-delivering RNAi compounds
KR101852210B1 (ko)	2010-03-24	2018-04-25	알엑스아이 파마슈티칼스 코포레이션	진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
JP6005628B2 (ja)	2010-04-28	2016-10-12	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
US9127033B2 (en)	2010-04-28	2015-09-08	Isis Pharmaceuticals, Inc.	5′ modified nucleosides and oligomeric compounds prepared therefrom
WO2011139695A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
ES2626006T3 (es)	2010-08-12	2017-07-21	Boehringer Ingelheim International Gmbh	Derivados de 6-cicloalquil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como inhibidores de PDE9A
EP2453017A1 (en)	2010-11-12	2012-05-16	Antisense Pharma GmbH	Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases
US8809345B2 (en)	2011-02-15	2014-08-19	Boehringer Ingelheim International Gmbh	6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN102993255B (zh) *	2011-09-19	2016-02-10	上海兆维科技发展有限公司	2’-o-(2-甲氧乙基)-5-甲基尿苷和2’-o-(2-甲氧乙基)-5-甲基胞苷及其衍生物的制备及其纯化方法
US9920319B2 (en)	2013-05-03	2018-03-20	Council Of Scientific & Industrial Research	2′/3′/5′-(R/S)-serinyl functionalized oligonucleotides
EP3564374A1 (en)	2013-06-21	2019-11-06	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulation of target nucleic acids
EP3079707A4 (en)	2013-12-02	2017-10-18	RXi Pharmaceuticals Corporation	Immunotherapy of cancer
WO2015168108A2 (en)	2014-04-28	2015-11-05	Rxi Pharmaceuticals Corporation	Methods for treating cancer using nucleic targeting mdm2 or mycn
JP6836987B2 (ja)	2014-09-05	2021-03-03	フィオファーマシューティカルズコーポレーションＰｈｉｏＰｈａｒｍａｃｅｕｔｉｃａｌｓＣｏｒｐ．	Ｔｙｒまたはｍｍｐ１を標的とする核酸を用いて老化および皮膚障害を処置するための方法
EP3862005A1 (en)	2015-07-06	2021-08-11	Phio Pharmaceuticals Corp.	Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
WO2017007825A1 (en)	2015-07-06	2017-01-12	Rxi Pharmaceuticals Corporation	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
CA3002744A1 (en)	2015-10-19	2017-04-27	Rxi Pharmaceuticals Corporation	Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
WO2017142054A1 (ja)	2016-02-17	2017-08-24	国立大学法人東京工業大学	人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
CN111819285B (zh)	2018-01-09	2024-08-09	希博斯美国有限公司	防碎基因和突变
MX2020009765A (es)	2018-03-20	2021-01-08	Tokyo Inst Tech	Oligonucleotido antisentido reducido en toxicidad.
CN117858884A (zh)	2021-08-24	2024-04-09	日产化学株式会社	2’修饰鸟苷化合物的制造方法
WO2023054708A1 (ja)	2021-09-30	2023-04-06	日産化学株式会社	２'修飾ピリミジンヌクレオシドの製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4806463A (en) *	1986-05-23	1989-02-21	Worcester Foundation For Experimental Biology	Inhibition of HTLV-III by exogenous oligonucleotides
EP0266099A3 (en) *	1986-10-28	1990-09-19	The Johns Hopkins University	Oligonucleoside alkyl or arylphosphonate derivatives capable of crosslinking with or cleaving nucleic acids
AU636573B2 (en) *	1988-02-26	1993-05-06	Worcester Foundation For Biomedical Research, Inc.	Inhibition of htlv-iii by exogenous oligonucleotides
EP0497875B1 (en) *	1989-10-24	2000-03-22	Isis Pharmaceuticals, Inc.	2' modified oligonucleotides
US5212295A (en) *	1990-01-11	1993-05-18	Isis Pharmaceuticals	Monomers for preparation of oligonucleotides having chiral phosphorus linkages
EP0604409B1 (en) *	1990-01-11	2004-07-14	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs for detecting and modulating rna activity and gene expression
JPH0813274B2 (ja) *	1990-08-13	1996-02-14	アイシス・ファーマシューティカルス・インコーポレーテッド	遺伝子発現を検出及び変調する糖修飾されたオリゴヌクレオチド
ATE317848T1 (de) *	1991-12-24	2006-03-15	Isis Pharmaceuticals Inc	Unterbrochene 2'-modifizierte oligonukleotide
AU4684993A (en) *	1992-07-23	1994-02-14	Isis Pharmaceuticals, Inc.	Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof

1994
- 1994-05-03 DK DK94810255T patent/DK0626387T3/da active
- 1994-05-03 DE DE59407895T patent/DE59407895D1/de not_active Expired - Lifetime
- 1994-05-03 EP EP94810255A patent/EP0626387B1/de not_active Expired - Lifetime
- 1994-05-03 ES ES94810255T patent/ES2128535T3/es not_active Expired - Lifetime
- 1994-05-03 AT AT94810255T patent/ATE177430T1/de active
- 1994-05-10 IL IL10960594A patent/IL109605A/xx not_active IP Right Cessation
- 1994-05-10 IL IL12333094A patent/IL123330A/xx not_active IP Right Cessation
- 1994-05-10 CA CA002123241A patent/CA2123241C/en not_active Expired - Lifetime
- 1994-05-11 AU AU63044/94A patent/AU687796B2/en not_active Expired
- 1994-05-11 CN CN94105715A patent/CN1100728A/zh active Pending
- 1994-05-12 JP JP12295794A patent/JP4012579B2/ja not_active Expired - Lifetime
1995
- 1995-06-02 US US08/459,434 patent/US5969116A/en not_active Expired - Fee Related
1998
- 1998-02-17 IL IL12333098A patent/IL123330A0/xx unknown

Also Published As

Publication number	Publication date
IL123330A (en)	1999-12-31
IL109605A (en)	1999-12-31
JP4012579B2 (ja)	2007-11-21
EP0626387A1 (de)	1994-11-30
US5969116A (en)	1999-10-19
DE59407895D1 (de)	1999-04-15
JPH072889A (ja)	1995-01-06
IL123330A0 (en)	1998-09-24
AU687796B2 (en)	1998-03-05
CA2123241A1 (en)	1994-11-13
IL109605A0 (en)	1994-08-26
CA2123241C (en)	2007-02-13
AU6304494A (en)	1994-11-17
CN1100728A (zh)	1995-03-29
EP0626387B1 (de)	1999-03-10
ES2128535T3 (es)	1999-05-16
ATE177430T1 (de)	1999-03-15

Publication	Publication Date	Title
DK0626387T3 (da)	1999-09-27	Nukleosider og oligonukleotider med 2'-ethergrupper
BG95575A (bg)	1993-12-24	3'-(2')-амино-и тиолмодифицирани, свързани с флуоресциращо багрило нуклеозиди,нуклеотиди и олигонуклеотиди и метод за тяхното получаване и приложението им
ATE242260T1 (de)	2003-06-15	Sulfonatfreie cyaninfarbstoffe zur markierung von nukleosiden und nukleotiden
FI104176B1 (fi)	1999-11-30	Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi
NO303543B1 (no)	1998-07-27	Nukleosid-5'-trifosfat og fosforamiditt samt anvendelser derav
DE3751947D1 (de)	1996-12-12	Nucleosidderivate und ihre Verwendung in der Oligonucleotid-Synthese
DK0817785T3 (da)	2001-07-02	Substrater for beta-lactamase og anvendelse deraf
ES2106684A1 (es)	1997-11-01	2-hidroxifeniltriazinas.
ATE51872T1 (de)	1990-04-15	Adenosin-nukleosid-derivate, ihre herstellung und biologische verwendung.
ATE179983T1 (de)	1999-05-15	Antiretrovirale, enantiomere nukleotid-analoge
WO2002014439A3 (en)	2002-06-13	Process for producing coatings using surface-active photoinitiators
NO178500C (no)	1996-04-10	Spikamycinderivater, mellomprodukt samt antitumormiddel
DK0816368T3 (da)	2003-05-05	Kemisk phosphorylering af oligonukleotider og reaktanter anvendt dertil
CA2042745A1 (en)	1991-11-19	Novel hardenable compositions
WO1994009011A1 (de)	1994-04-28	Quartäre ammoniumgruppen enthaltende siloxanderivate, verfahren zu ihrer herstellung und ihre verwendung
ES2081192T3 (es)	1996-02-16	Inhibidor de timidina quinasa viral del herpes simple.
IE812876L (en)	1982-06-09	Ethers of substituted hydroxymethylpyrazines
IL90972A0 (en)	1990-02-09	Process for the preparation of halosilanes
TH13566A (th)	1993-12-15	พิริดิโน-, พิร์โรลิดิโน-และแอ ซิพิโน-ซับสทิทิวเทด ออกซีมออกซีมซึ่ง มีประโยชน์เป็นสารต่อต้านอาเธอ โรสเคลอโร
JPS5726699A (en)	1982-02-12	Guanosine derivative